Clinical Trials

Imbrium Therapeutics LP, a subsidiary of Purdue Pharma LP, announced positive preliminary results from a phase 2 study of an investigational oral treatment for patients with insomnia during recovery from an alcohol use disorder.

Up to one-quarter of those seeking clinical trial enrollment for novel front-line therapies to treat diffuse large B-cell lymphoma are excluded based on organ function laboratory values, study results showed.

PHILADELPHIA — Non-Hispanic white patients are overrepresented while Black and Hispanic patients are underrepresented in pivotal psoriatic arthritic clinical trials, according to data presented at ACR Convergence 2022.

Clinical-stage biopharmaceutical company Clene Inc. announced proof-of-concept evidence of potential neuroprotective effects of CNM-Au8, an oral therapeutic for patients with stable relapsing-remitting MS.

Lecanemab reduced amyloid markers and slowed cognitive decline in patients with early Alzheimer’s disease, although not without risk for adverse events, according to new data published in The New England Journal of Medicine.

Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous administration of Tysabri rather than IV, citing shorter duration of delivery and convenience, per a presentation at ECTRIMS 2022.

Janssen has announced positive results from the phase 3 ESCAPE-TRD trial, which evaluated flexibly dosed intranasal esketamine for treatment-resistant major depressive disorder.

Prostate cancer clinical trials included significant underrepresentation of Asian, Black and Hispanic men based on incidence of the disease among these groups, results of meta-analysis published in JAMA Oncology showed.

Lysogene has announced topline results from its phase 2/3 study evaluating LYS-SAF302, an investigational gene therapy for the treatment of mucopolysaccharidosis type IIIA, or Sanfilippo syndrome.

The FDA has extended the Prescription Drug User Fee Act goal date to Dec. 28, for TG Therapeutics’ biologics license application of ublituximab for patients with relapsing forms of MS.